The UBS Q-GARP portfolio has outperformed the S&P 500 by over 5% year to date, and there’s no reason to think that the performance will not carry through and continue in 2016.
The health care sector may have sold off a fair amount since this past summer, but there is some M&A action between giants in the sector that has potential to heat it…
Last week, a few biotech companies made absolutely massive runs, and some had serious falls.
Allergan has issued a press release that confirms some of the rumors floating in the market that it has been approached by Pfizer.
With specialty pharmaceutical stocks having the chance to move dramatically higher, three large cap leaders are RBC's favorites now.
Martin Shkreli has said he would lower the price of Daraprim back down but hasn’t actually done it. He probably figures that if he can outlast the initial wave of negative publicity,…
We scanned the Merrill Lynch stock coverage universe for specialty pharmaceutical stocks rated Buy and found three top companies that have been crushed.
A new research report from UBS makes an interesting switch in the Quality Growth At a Reasonable Price (Q-GARP) portfolio.
Allergan is scheduled to report its second-quarter financial results Thursday before the markets open.
Chris Lange In a new report, UBS made changes in the firm's Equity Focus list and updated other positions.
In a new research report, Cowen's well-respected analyst Ken Cacciatore makes a very good case that some huge, high-profile biotech companies could be targeted for buyouts.
ThinkstockTeva Pharmaceutical Industries Ltd. (NYSE: TEVA) may have just proved how financially fit and capable the company is. On Friday afternoon the global generic drug giant reported that it has secured financing…
Allergan and Kythera Biopharmaceuticals announced that they have entered into a definitive agreement in which the former will acquire he latter in a cash and equity transaction valued at roughly $2.1 billion.
Chris Lange American Airlines will be the newest addition to the S&P 500, taking the place of Allergan.
Salix Pharmaceuticals and Valeant Pharmaceuticals have announced that they had entered into an agreement on their plan to merge based on a new price for Salix shares.
